House Seeks FDA Reports on Pharmacy Tied to Meningitis
This article is for subscribers only.
Lawmakers probing the U.S. meningitis outbreak are focusing on why the pharmacy linked to this year’s infections didn’t receive greater scrutiny when potential regulatory violations were found six years ago.
The House Energy and Commerce Committee sent a letter yesterday to Margaret Hamburg, the commissioner of the Food and Drug Administration, asking her about inspections at New England Compounding Center dating to 2004. The committee cited an FDA warning in 2006 of “potential microbial contamination” and asked the agency to document what follow-up occurred.